Qiagen NV (NYSE:QGEN)
$ 45.635 -0.355 (-0.77%) Market Cap: 10.12 Bil Enterprise Value: 10.81 Bil PE Ratio: 30.24 PB Ratio: 2.81 GF Score: 86/100

Qiagen NV at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 03:30PM GMT
Release Date Price: $46.31 (-1.99%)
Peter James Welford
Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst

I think this is the last thing between you and lunch. So stick with it, and we're going to. My name is Peter Welford. I'm the European Pharma Biotech and Life sciences analyst at Jefferies in London. It's my pleasure to host the next company in this track, which is QIAGEN. We'll be doing a fireside chat. It's our pleasure to have here today, the CFO, Roland, who is going to make a few introductory comments. After that, we'll get straight into Q&A. (Operator Instructions). With that, over to Roland or I should say, we have got John Gilardi as well of IR on the front as well. So with that, over to Roland, and thank you very much.

Roland Sackers
Qiagen N.V. - CFO, MD & Member of Management Board

Yes. Thanks, Peter, for having us. It is always good to see people in person. Yes, let me kick it off a bit with just a brief summary where we are. And I am quite sure that most of you have seen in our press release and the Q1 results, which I do

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot